PT - JOURNAL ARTICLE AU - Claire Hodgekiss AU - S. Hasan Arshad AU - Graham Roberts AU - Susan Grevatt AU - Ramesh Kurukulaaratchy TI - The effect of persistence of persistent childhood wheeze through adolescence on lung function at 18-years AID - 10.1183/13993003.congress-2016.PA1313 DP - 2016 Sep 01 TA - European Respiratory Journal PG - PA1313 VI - 48 IP - suppl 60 4099 - http://erj.ersjournals.com/content/48/suppl_60/PA1313.short 4100 - http://erj.ersjournals.com/content/48/suppl_60/PA1313.full SO - Eur Respir J2016 Sep 01; 48 AB - It is unclear what the long term consequences are in children who continue to wheeze into adulthood compared to those in whom it subsides. To assess this, the Isle of Wight Birth Cohort (n=1,456) was reviewed at 1, 2, 4, 10 and 18-years with recording of current wheeze at each visit. At 10-years, 4 wheeze phenotypes were defined. Persistent-Wheezers (PW) wheezed in the first 4 years of life and at 10-years (n = 125). We studied these individuals again at 18-years and compared those within this group who were still wheezing (n = 72) versus those who were not (n =53).The results show that those PW still wheezing at 18 had reduced 18-year lung function in terms of FEV1 (3.7L vs 4.1L p=0.047), reduced FEV1/FVC ratio (0.81 vs 0.85 p=0.029) and FEF25-75 (3.6L vs 4.5L p=0.001), as well as a significantly greater level of reversibility to salbutamol (9.7% vs 5.0%p=0.021). There was also evidence of significantly reduced lung development from 10 to 18-years in PW still wheezing throughout the large (FEV1% change 44% vs 51% p=0.009) and small airways (FEF25-75 % change 38% vs 45% p=0.037) plus in terms of FVC % change (46% vs 52% p=0.032). However there was no significant difference in 10-year lung function parameters for those PW who continued to wheeze into adulthood and those who didn't.In conclusion, different adolescent trajectories of lung function are seen in PW who outgrow or continue with their disease into adulthood. Those who continue to experience disease through adolescence demonstrate reduced adolescent lung growth and impaired lung function at 18-years.